Nucleotide sequences of a T. pallidum rare outer membrane protein

ABSTRACT

Antigenic rare outer membrane proteins of Spirochaetaceae are obtained from organisms extracted from infected tissue by a novel process of isolation utilizing a discontinuous Ficoll gradient separation, release of outer membrane in a low isotonic and low pH buffer and identification of outer membrane by use of a lipid soluble dye. Four antigenic rare outer membrane proteins of T. pallidum subsp. pallidum useful in diagnosis and prophylaxis of syphilis are provided. Also provided is the amino acid sequence of a rare outer membrane protein of T. pailidum subsp. pallidum and the nucleotide sequence encoding it.

This work was supported by U.S. Government NIH grant AI 21352 and AI29733.

This is a divisional of application Ser. No. 08/292,904, filed Aug. 17,1994, now abandoned, which is a continuation in part of Ser. No.08/255,322, filed Jun. 7, 1994, now abandoned, which is a continuationin part of Ser. No. 08/178,084, filed Jan. 6, 1994, now abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to methods for isolation of rare proteins frombacterial samples. More particularly, this invention relates to a methodfor isolating rare outer membrane proteins from the familySpirochaetaceae, such as genus Treponema and to the use of such proteinsin diagnosis and prophylaxis of related diseases.

2. Description of Related Art

The genus Treponema (order Spirochaetales, family Spirochaetaceae), atype of gram-negative bacteria, contains four human pathogens as well asat least six nonpathogens. The pathogens are characterized by an extremesensitivity to environmental conditions that renders them impossible toculture in vitro. Due to DNA homology the agents that cause syphilis,yaws and endemic syphilis have been combined into one species and threesubspecies: T. pallidum subsp. pallidum (syphilis); T. pallidum subsp.pertenue (yaws); and T. pallidum subsp. endemicum (endemic syphilis). T.carateum, which is the causative agent of pinta, remains a separatespecies. Syphilis is found worldwide, yaws is endemic in the tropics,pinta is prevalent in tropical areas of Central and South America, andendemic syphilis is restricted to desert regions. These treponemalinfections are very complex, each exhibiting distinct stages ofsymptomatic manifestations followed by asymptomatic periods. Withoutantibiotic therapy, these diseases are chronic and may last for 30 to 40years.

To date, the four pathogens have been considered antigenicallyidentical. An individual subspecies-specific antigen has not beenidentified and serological reactions demonstrate immunologicalrelatedness. Both Wassermann and anti-T. pallidum subsp. pallidumantibodies develop in response to each treponemal disease, and knownprotective immunogens are also related, as shown by cross-resistance (T.S. Turner, et al., Biology of the Treponematoses. W.H.O Monogr. Ser.35:1-277, 1957). Therefore, the geographical location together with theclinical manifiestations of the patient have been considered the key todiagnosis (Manual of Clinical Microbiology, 5th Ed., A. Balows, et al.,Eds., p 567, 1991).

Freeze-fracture electron microscopy of outer membranes from pathogenicspirochetes has revealed that their integral transmembrane outermembrane protein density is one to two orders of magnitude less thanthat of typical gram negative bacterial pathogens. It has been proposedthat this low outer membrane composition, and thus low surface exposureof antigenic target molecules, allows these organisms to effectivelyevade the host immune response, contributing to the chronic nature ofinfection exhibited by all spirochetal pathogens.

As is well known, the outer membranes of spirochetes, including that ofTreponema pailidum subsp. pallidum, the agent of syphilis, are fragilestructures as compared to those of typical gram negative bacteria.Consequently, separation of the outer membrane from the inner membranehas proven extremely difficult. Certain other medically relevantspirochetal bacteria with outer membrane structure and, hence, proteinstructure, similar to those of T. pallidum include Borrelia burgdorferi(Lyme Disease), Borrelial species (relapsing fever), and Leptospiralspecies (leptospirosis).

The outer membrane of T. pallidum has been found to be antigenicallyinert and resistant to specific treponemidical antibody (Radolf, et al.,Infect. Immun., 52:579, 1986; Hovind-Hougen, et al., Acta Pathol.Microbiol. Scand., 87:263, 1979; Nelson, et al., J. Exp. Med., 89:369,1949). Yet freeze-fracture electron microscopy has shown that certainrare outer membrane protein (tromp) molecules of T. pallidum havesurface exposed antigenic sites that bind antibody present in the serumof challenge immune animals (Blanco, et a., J. Immunol., 144:1914-1921,1990). Taken together the spirochetal bacterial pathogens imperil thehealth of a considerable portion of the human population, yetdevelopment of effective and specific vaccines and isolation of antigenscapable of generating protective immune response has been hampered by aconsiderable number of problems associated with this organism: theimpossibility of culturing the T. pallidum in vitro, the limited numbersof organisms that can be obtained from infected animals, thecontamination of treponemes by host tissue components, the fragility ofthe treponemal outer membrane, and the difficulty of isolating andidentifying the outer membrane proteins of pathogenic spirochetes.

Previous studies attempting to identify transmembrane outer membraneproteins of pathogenic spirochetes have utilized various detergentsolubilization approaches. Spirochetal outer membranes bleb from theunderlying protoplasmic cylinder under relatively mild conditions,including dilute detergents and hypotonic environments. However, suchapporaches have identified only abundant subsurface located proteins,including various lipoproteins which by definition are not transmembranemolecules and do not form particles viewed by freeze-fracture analysis.

Therefore, the need exists for new and better vaccines based upon theidentification of virulence related outer membrane molecules to be usedin diagnosis and for prophylaxis of diseases related to the pathogenicspirochetal bacteria, especially the genus T. pallidum.

SUMMARY OF THE INVENTION

A novel method is provided for isolating outer membrane of pathogenicSpirochaetacae family without use of detergents. The pathogen ispurified from contaminating host components using a density gradientcentrifugation medium that is stable at pH from about 3.2 to about 3.0,preferably a Ficoll step gradient. The purified pathogen is treated witha lipid soluble chromophore that intercalates into outer membrane toprovide a visual marker of membrane matter. Outer membrane is releasedfrom protoplasmic cylinders using a hypotonic, low pH buffer, preferablycitrate, followed by density gradient centrifugation, which yields, forexample, the chromophore labeled bands at 7% and 35% sucrose (wt/vol)for T. pallidum and T. vincentii, respectively. Freeze-fracture electronmicroscopy of membrane vesicles from the spirochete reveals an extremelylow density of protein particles. For instance, the particle density ofT. pallidum is approximately six times less than that of T. vincentii.Comparative immunoblot analysis of the T. vincentii membrane material tothat of whole organisms showed a lipopolysaccharide (LPS) ladderconsistent with 20% recovery of the outer membrane. Immunoblots of T.vincentii outer membrane also showed two antigenic proteins at 55- and65-kDa.

¹²⁵ I-penicillin, which binds only to inner membrane and not to outermembrane, was used to detect the presence of any inner membrane in theouter membrane preparation isolated according to the method of theinvention. No penicillin binding proteins in the T. pallidum membranematerial were detected, indicating the absence of inner membranecontamination.

Immunoblot analysis of T. pallidum outer membrane using antibodiesspecific for periplasmic associated proteins showed no detection ofknown 19-kDa "4D" protein or the 47-kDa lipoprotein and only traceamounts of endoflagellar protein. Rare outer membrane proteinsassociated with the T. pallidum were detected by one and two dimensionalreducing SDS-PAGE separation and immunoblot analysis, using goldstaining and serum from infected and challenge immune animals. Ascompared to whole organism preparations, four of the isolated proteinswere obtained in significantly enriched amounts from the outer membranepreparation.

Methods are provided for the use of outer membrane proteins ofpathogenic Spirochaetacae family for detection and amelioration ofassociated disease states.

The isolation of the T. pallidum outer membrane and identification ofits protein constituents has been complicated by the fragility of thisstructure, the limited number of treponemes that can be acquired byrabbit infection, and the significant amount of host contaminatingprotein following extraction of organisms from infected animals.Moreover, freeze-fracture electron microscopy has revealed that theouter membrane of T. pallidum contains two orders of magnitude lessintegral membrane protein than typical gram negative bacteria (Radolf,et a., Proc. Natl. Acad. Sci. USA, 86:2051-2055,1989; Walker, et al., J.Bacteriol., 171:5005-5011, 1989). Because of the paucity of T. pallidumrare outer membrane protein (TROMP), it is likely that previous studiesusing detergent extraction of T. pallidum to identify transmembraneouter membrane proteins have mistakenly identified as outer membraneproteins abundant subsurface molecules, including lipoproteins anchoredin the inner membrane that are released by such treatments (Chamberlain,et al., Infect. Immun., 57:2872-2877, 1989; Penn, et al., Immunology,46:9-16, 1982; Penn, et al., J. Gen. Microbiol., 131:2349-2357, 1985).

It has previously been shown that while 0.1% Triton X-114 canselectively solubilize the T. pallidum outer membrane, some subsurfacemolecules, including the 47-kDa lipoprotein, are also released (Radolf,et al., Infect. Immun., 56:490-498, 1988). Concentrations of TritonX-114 of up to 2% have been shown to release additional T. pailidumlipoproteins (Cunningham, et al., J. Bacteriol., 170:5789-5796, 1988;Radolf, et al, supra, 1988).

The present invention provides a method for isolating the outermembranes from treponemes and other spirochetes with rare outer membraneproteins in the absence of detergents. In the examples herein thisprocedure was applied to T. vincentii, which, because of the LPS contentof its outer membrane, was used as a marker for outer membrane recovery.Preliminary studies showed that while a hypotonic osmotic environmentcaused significant blebbing of the treponemal outer membrane, only asmall amount of outer membrane was released. Endoflagellar filaments mayphysically interact with the outer membrane in the process of motility(Berg, J. Theor. Biol., 56:269-273, 1976; Goldstein, et al., CellMotility and the Cytoskeleton, 9:101-110, 1988). These structures maylimit the release of outer membrane under hypotonic conditions.Therefore, in the present invention a low pH hypollonic buffer is usedto dissociate endoflagellar filaments (Blanco, et al., Infect. Immun.,56:168-175, 1988). As a result, the outer membrane is completelyreleased as viewed by electron microscopy. The low pH treatment,however, is incompatible with purification of T. pallidum by theconventional Percoll procedure due to the adverse effects of low pH onresidual Percoll, which solubilizes in low pH conditions. Therefore, inthe practice of this invention, T. pallidum is purified using acontinuous or discontinuous density gradient separation in a medium thatis stable in the pH range from 3.2 to 3.0, removes contaminating hostcomponents, and is also compatible with the subsequent low pHincubation.

A second key step in the practice of this invention is treatment oftreponemes with a chromophore, preferably one that intercalates intobiological and liposomal membranes. The preferred chromophore isoctyl-decyl rhodamine, but one skilled in the art will appreciate thatany chromophore of a size suited to intercalate into liposomal membranescan be used so long as it is naturally lipophilic or can be substitutedwith lipid-solubilizing moieties containing between 8 and 10 carbonatoms. In addition, the lipid-soluble chromophore should be selected soas not to significantly alter the membrane particle density. Use of thechromophore provides a visual marker to follow the disposition ofreleased outer membrane. To determine whether the chosen lipid-solublechromaphore alters membrane particle density, a pathogenic spirochetehaving an order of magnitude greater amount of outer membrane proteinthan the one being isolated can be used. For instance, using Borreliaburgdorferi, a pathogenic spirochete which has an order of magnitudegreater amount of outer membrane protein than T. pallidum (Walker, etal., supra, 1991), it was found that octyl-decyl rhodamine did notchange its outer membrane particle density (data not shown), suggestingthat the outer membrane proteins of T. pallidum and T. vincentii werealso not affected by this reagent.

The finding herein that T. pallidum outer membrane banded in a sucrosegradient at a very low density (7%) is consistent with membrane thatcontains a small amount of protein (Tomlinson, et al., Biochem.,28:8303-8311, 1989). This finding was further confirmed byfreeze-fracture electron microscopy of purified T. pallidum membranevesicles, which showed fracture faces that contained extremely rareintramembranous particles. This result is similar to the low particledensity observed by others for the native outer membrane of T. pallidum(Radolf, et al. supra; Walker, et al., supra). By comparison, the T.vincentii outer membrane banded in a sucrose gradient at a higherdensity (35%) as is consistent with the greater amount ofintramembranous particles observed in its membrane and/or is consistentwith a membrane that contains lipopolysaccharide (LPS).

The selective isolation of the T. pallidum outer membrane from theprotoplasmic cylinder was determined by the use of penicillin bindingproteins (PBPs) as a marker to visualize inner membrane associatedproteins. Previously studies have shown that T. pallidum PBPs remainwith the protoplasmic cylinders following solubilization of the outermembrane in the detergents Triton X-114 or Triton X-100 (Cunningham, etal., J. Bacteriol., 169:5298-5300, 1987; Radolf, et al., Infect. Immun.,57:1248-1254, 1989). No PBPs were detected with purified outer membraneprepared according to the method of this invention, indicating that theprocedure selectively removes only the outer membrane, free fromcontamination by inner membrane.

Of particular significance is the complete absence of the T. pallidumouter membrane preparation of the 4D protein and the 47-kDa majorlipoprotein, and the finding of only trace amounts of endoflagellarprotein, indicating little to no contamination by these periplasmiccomponents. The 47-kDa lipoprotein, one of the most abundant T. pallidummolecules, was not detected in the outer membrane preparation, thusconfirming that inner membrane anchored lipoproteins were not releasedby this procedure.

Coomassie stained SDS-PAGE and immunoblot analysis of 1×10⁹ T. vincentiiequivalents of outer membrane revealed two major antigenic proteinspecies of 65- and 55-kDa. In contrast, Coomassie stained SDS-PAGE of a5-fold greater amount of T. pallidum outer membrane showed no detectableprotein. These findings are consistent with the observations offreeze-fracture electron microscopy indicating that the outer membraneparticle density of T. pallidum is six times less than that of T.vincentii. From the outer membrane particle density of T. pallidum,which has been determined to be 170 particles/um² and the surface areaof T. pallidum, which is approximately 4 um², it is calculated that5×10⁹ T. pallidum should contain only 250 nano grams of outer membraneprotein based upon a single species of 50K molecular weight. Therefore,the amount of a single species of TROMP isolated using the method ofthis invention is several hundred times less than was previouslyerroneously identified by prior art methods (Norris, et al., Microbiol.,57:750-779, 1993).

Enhanced chemiluminescence (ECL) immunoblotting has the sensitivity ofdetecting pico grams of antigen (ECL Western Blotting protocols,Buckinghamshire, England, 1993). Therefore, this technique is preferablyemployed in the method of this invention for detecting outer membraneassociated protein. Most preferably, using ECL, immunoblots of outermembrane samples are prepared in urea and electrophoresed in onedimension or following two dimensional (2D) electrophoresis, and probedwith sera from rabbits with immunity to the pathogenic treponeme ofinterest. Using this technique upon T. pallidum showed two majorantigenic protein bands at 17- and 45-kDa. The 17-kDa protein had a pIof greater than 7.0, showed higher oligomeric forms, and selectivelypartitioned into the hydrophobic phase following Triton X-114 detergentextraction (data not shown).

These findings are consistent with the properties of the native andrecombinant 17-kDa lipoprotein of T. pallidum (Atkins, et al., Infect.Immun., 61:1202-1210, 1993). It was also shown using specific monoclonalantibodies that the 45-kDa protein was the previously characterized TmpAlipoprotein (Schouls, et al., Microb, Pathog., 7:175-188, 1989; Hansen,et al., J. Bacteriol., 162:15227-1237, 1985). While the vast majority ofthese two proteins remain associated with the protoplasmic cylinderfollowing outer membrane removal (data not shown), some of the 17- and45-kDa lipoproteins are specifically associated with outer membrane.

In addition to the strongly antigenic 17- and 45-kDa lipoproteins of T.pailidum isolated, gold-stained 2D blots of 3×10¹⁰ treponemalequivalents revealed four additional T. pallidum proteins, including oneeach at 28- and 65 kDa, and two at 31-kDa. All of these proteins havebeen found to contain antigenic sites reactive with sera from immunerabbits. Comparison of the pI's of these found proteins to those on 2Dblots of 5×10⁸ whole organisms have shown that the 31-kDa (acidic pI)and 28-kDa proteins correspond to prominent T. pallidum protein spots onimmunoblots and may be additional outer membrane associated lipoproteinsnot heretofore identified. In contrast, the 31-kDa protein (basic form)corresponds to a minor and faintly detectable protein spot on 2D blotsof whole organisms, while the 65-kDa protein does not correspond to anypreviously identified T. pallildum protein. In view of their significantenrichment following outer membrane isolation, the 31-kDa (basic pI) and65-kDa proteins are identified as rare outer membrane proteins.

The outer membrane proteins of typical gram negative bacteria include anexport signal cleaved by leader peptidase I, and amphiphathic betapleated sheet structure throughout the secondary sequence that generatesmembrane spanning regions (Vogel, et al., J. Mol. Biol., 190:191-199,1986; Weiss, et al., Science, 254:1627-1630, 1991; Von Heijne, J. Mol.Biol., 184:99-105, 1985). Recently, the gene encoding a surface exposed31-kDa protein of Leptospira alstoni, designated Omp-LI (outer membraneprotein of Leptospira), has been cloned, sequenced, and expressed(Haake, et al., J. Bacteriol., 175:42954234, 1993). The deduced aminoacid sequence of this protein shows an export and amphiphatic betapleated sheet topology resulting in 10 membrane spanning domains (Haake,et al., supra). The structural similarity between this putative outermembrane protein of Leptospira and those of typical gram negativebacteria suggests that other spirochetal outer membrane proteins may bestructurally similar to those of typical gram negative bacteria. TheLeptospira outer membrane has been isolated using the method of thisinvention. The membrane material purified was found to selectivelycontain lipopolysaccharide like substance (LLS), which is unique to theLeptospira outer membrane (Zeigler, et al., Can. J. Microbiol.,21:1102-1112, 1975), and several proteins including OMP-LI. Thesefindings provide additional evidence that the membrane material andassociated protein isolated by the method of this invention from T.pallidum is outer membrane in origin.

The binding of antibody in immune serum to virulent T. pallidum resultsin aggregation of TROMP particle as viewed by freeze fracture electronmicroscopy (Blanco, et al., supra, 1990). These findings have recentlybeen confirmed and extended using serum obtained from animals withvarying degrees of challenge immunity. Particle aggregation directlycorrelates with the development of challenge immunity, suggesting thatTROMP are key targets for a protective host immune response.

In addition, due to isolation and purification of the T. pallidum outermembrane, the amino acid sequence of the protein has been obtained andof DNA encoding it and for cloning of TROMP molecules. The recombinantexpression of these rare outer membrane proteins can be used forexperimental biology studies to address directly the molecular basis forT. pallidum pathogenesis, for diagnostic tests to detect syphilis andfor development of host immunity during syphilis.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B are an SDS-PAGE autoradiograph showing comparativeanalysis of 5×10⁸ unpurified and Ficoll purified T. pallidum (Tp). Themolecular weights (×10³) of marker standards (MKs) are indicated.

FIG. 1A shows a Coomassie stained SDS-PAGE gel.

FIG. 1B shows immunoblots probed with anti-rabbit serum proteins.

FIGS. 2A-2D show electron micrographs of outer membrane materialisolated from T. pallidum (Tp) and T. vincentii(Tv).

FIG. 2A shows a whole mount electron micrographs of Tp purified onFicoll and labeled with rhodamine and Tv washed with PBS and labeledwith rhodamine.

FIG. 2B shows a whole mount electron micrographs of Tp and Tv organismstreated with acidic citrate buffer, showing release of outer membrane.

FIG. 2C shows a whole mount electron micrographs of Tp and Tv outermembrane vesicles purified on sucrose gradient.

FIG. 2D shows a freeze fracture electron micrographs of purified Tp andTv outer membrane vesicles. Bar indicates 0.5 μm.

FIG. 3 shows an immunoblot analysis of T. vincentii, untreated andtreated with proteinase K (PK), showing 2×10⁸ equivalents of wholeorganisms (WO) and protoplasmic cylinders (PC) and 1×10⁹ equivalents ofouter membrane (OM). The molecular weights (×10³) of marker standardsare indicated.

FIG. 4 an SDS-PAGE autoradiograph showing penicillin binding proteinsfrom 1×10⁸ whole organisms (WO) and protoplasmic cylinders (PC) of T.pallidum and from 5×10³ equivalents of outer membrane (OM). Themolecular weights (×10) of marker standards are indicated.

FIG. 5 shows an immunoblot analysis of outer membrane material of T. T.pallidum probed with antisera against three periplasmic associatedproteins: whole organisms (Tp), outer membrane (OM) are probed withanti-endoflagellar serum (αEF); anti-19-kDA "4D" serum (α4D); andmonoclonal antibody against 47-kDa lipoprotein (α47 MAb). The molecularweights (×10³) of marker standards are indicated.

FIG. 6 is an immunoblot showing immune rabbit serum (IRS) detection ofT. pallidum outer membrane associated proteins. The molecular weights(×b 10 ³) of marker standards are indicated (+ indicates treatment with8M urea).

FIG. 7 is an SDS-PAGE immunoblot showing immune rabbit serum (IRS)detection of T. pallidum outer membrane associated proteins separated bytwo dimensional gel electrophoresis. The molecular weights (×10³) ofmarker standards are indicated. The isoelectric focus (EIF) range from 7to 5 is indicated by a bar at the top.

FIG. 8 shows gold staining detection of T. pallidum outer membraneassociated proteins separated by two dimensional gel electrophoresis.Arrows and bracket indicate T. pallidum proteins identified, includingendoflagella (EF) and TmpA. The molecular weights (×10³) of markerstandards are indicated. The isoelectric focus (EIF) range from 7 to 5is indicated by a bar at the top.

FIGS. 9A and 9B shows the nucleotide sequence for an open reading frameidentified in the 872 bp HindIII fragment in the DNA of the 31 kDa TROMPprotein (pI 6.7). The nucleotide sequence encodes a precursor TROMPprotein of 288 amino acids known as TROMP1 (SEQ ID NOS:1 and 2).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides isolated and purified rare outer membraneproteins and protein fragments of the pathogenic Spirochaetacae family,especially of the genus Treponema, and a method for their isolation.These immunogenic proteins are useful in a pharmaceutical compositionfor inducing an immune response to pathogenic Spirochaetacae from whichthey are derived. Hence, the rare outer membrane proteins of thisinvention are useful for ameliorating the effects of disease statesassociated with the pathogen from which they are derived. In addition,the rare outer membrane proteins, which contain antigenic epitopes forantibodies found in the blood of infected mammals, such as humans, canbe used to detect individuals infected with disease states associatedwith the pathogens from which the proteins are derived. Alternatively,antibodies generated from immunization of an individual with the rareouter membrane proteins can be used to detect exposure to or infectionby the pathogen in another individual.

The preferred outer membrane proteins of this invention are isolatedfrom the outer membrane of the genus Treponema pallidum subsp. pallidum,the pathogen responsible for causing syphilis in humans, and arecharacterized by the following isoelectric focus points and molecularweights, as determined by reducing SDS-PAGE as shown in Table 1.

                  TABLE 1                                                         ______________________________________                                        Protein       Molecular weight                                                                              pl                                              ______________________________________                                        ROM 1         31 kDa          6.6                                             ROM 2         65 kDa          5.9-6.0                                         ROM 3         28 kDA          6.9-7.0                                         ROM 4         31 kDa          6.5                                             ______________________________________                                    

A novel method for isolating outer membrane of pathogenic Spirochaetacaefamily is presented herein. The pathogen is purified from contaminatedhost components, such as tissue, blood, bodily secretions, and the like,preferably using a discontinuous Ficoll step gradient of at least foursteps. It is preferred that the densities of the discontinuous stepgradient be as follows: 1.045, 1.055, 1.065 and 1.085 g/ml. The purifiedpathogen is treated with a lipid soluble chromophore that intercalatesinto outer membrane, to provide a visual marker of membrane matter. Thelipid-soluble chromophore is preferably a dye marker, most preferably afluorescent dye marker substituted with one or more branched orunbranched alkyl chains, each containing from about 8 to 10 carbonatoms.

Outer membrane is released from protoplasmic cylinders without use ofdetergent using a hypotonic, low pH buffer followed by density gradientcentrifugation to obtain the chromophore labeled band. The buffer iskept at pH from about 3.2 to about 3.0, and the buffer is preferablycitrate or acetate. Preferably, the buffer has an ionic strength of 50mM to 100 mM.

The density gradient centrifugation medium must be selected to be stablewithin the low pH range of the buffer. Generally, any polymeric densitygradient centrifugation medium having stability at pH within the rangefrom about 3.2 to 3.0 can be used, but preferably the medium is apolymeric saccharide medium such as FICOLL®, a synthetic polymer ofsucrose, or FICOLL HYPAQUE® density gradient medium. The centrifugationmedium can be either continuous or discontinuous, but preferably in thepractice of this invention the density range is from about 1.045 toabout 1.085 g/ml. Although any workable means can be used, the bandcontaining the chromophore labeled band is preferably separated from thesucrose gradient medium by needle aspiration.

Antibodies provided in the present invention are immunoreactive with atleast one Spirochaetales ROM protein of the pathogen of interest.Antibody which consists essentially of pooled monoclonal antibodies withdifferent epitopic specificities, as well as distinct monoclonalantibody preparations are provided. Monoclonal antibodies are made fromantigen-containing fragments of the protein by methods well known in theart (Kohler, et al., Nature, 256:495, 1975; Current Protocols inMolecular Biology, Ausubel, et al., ed., 1989). The term antibody, orimmunoglobulin, as used in this invention includes intact molecules aswell as fragments thereof, such as Fab and F(ab')₂, that are capable ofbinding an epitopic determinant on a Spirochaetales ROM, such as theROMs of T. pallidum shown in Table 1.

Minor modifications of primary amino acid sequence may result inproteins that have substantially equivalent function compared to the ROMproteins described herein. Such modifications may be deliberate, as bysite-directed mutagenesis, or may be spontaneous. All proteins producedby these modifications are included herein as long as the antigenicfunction of the modified ROM.

Modifications of the ROM protein primary amino acid sequence alsoinclude conservative variations. The term "conservative variation" asused herein denotes the replacement of an amino acid residue by another,biologically similar residue. Examples of conservative variationsinclude the substitution of one hydrophobic residue such as isoleucine,valine, leucine or methionine for another, or the substitution of onepolar residue for another, such as the substitution of arginine forlysine, glutamic for aspartic acids, or glutamine for asparagine, andthe like. The term "conservative variation" also includes the use of asubstituted amino acid in place of an unsubstituted parent amino acidprovided that antibodies raised to the substituted polypeptide alsoimmunoreact with the unsubstituted polypeptide.

The invention extends to any host modified according to the methodsdescribed, or modified by any other methods, commonly known to those ofordinary skill in the art, such as, for example, by transfer of geneticmaterial using a lysogenic phage, and which result in a prokaryoteexpressing the Spirochaetales gene for protein. Prokaryotes transformedwith the Spirochaetales gene encoding the ROM protein are particularlyuseful for the production of polypeptides which can be used for theimmunization of an animal.

In one embodiment, the invention provides a pharmaceutical compositionuseful for inducing an immune response in an animal to pathogenicSpirochaetales, preferably a Treponema, most preferably T. pallidum. Thecomposition comprises an immunologically effective amount of anantigenic outer membrane protein in a pharmaceutically acceptablecarrier. The term "immunogenically effective amount," as used indescribing the invention, is meant to denote that amount ofSpirochaetales antigen that is necessary to induce in an animal theproduction of an immune response to Spirochaetales. The rare outermembrane protein of the invention are particularly useful in sensitizingthe immune system of an animal such that, as one result, an immuneresponse is produced which ameliorates the effect of Spirochaetalesinfection. For instance, an immune response to T. pallidum can beproduced by administering to an animal the ROM proteins of Table 1isolated by the method of this invention.

In another embodiment as shown in FIGS. 9A and 9B, the inventionprovides the amino acid sequence of a 288 amino acid precursor proteinfragment (TROMP1) of the 31 kDa protein of this invention (SEQUENCE I.D.NO. 1). TROMP1 is encoded by a DNA open reading frame of 867 bp(SEQUENCE I.D. NO. 2) isolated using tryptic digest amino acid sequenceanalysis of the genomic DNA of T. pallidum, which had been previouslydigested with EcoRI restriction enzyme. A segment comprising the first32 residues from the N-terminus of the precursor protein hascharacteristics of a hydrophobic signal peptide including a 13 residueN-region containing four basic charged residues (Histidine, Lysine,Histidine, and Arginine), an H-region containing 11 consecutivehydrophobic amino acids, and a C-region containing a putative concensusleader peptidase I cleavage site of Threonine-Histidine-Alanine. Themature processed protein consists of 256 amino acids with a calculatedmass of 28,182 Da.

A T. pallidum rare outer membrane protein can be administeredparenterally by injection, rapid infusion, nasopharyngeal absorption,dermal absorption, or orally. Pharmaceutically acceptable carrierpreparations for parenteral administration include sterile or aqueous ornon-aqueous solutions, suspensions, and emulsions. Examples ofnon-aqueous solvents are propylene glycol, polyethylene glycol,vegetable oils such as olive oil, and injectable organic esters such asethyl oleate. Carriers for occlusive dressings can be used to increaseskin permeability and enhance antigen absorption. Liquid dosage formsfor oral administration may generally comprise a liposome solutioncontaining the liquid dosage form. Suitable forms for suspending theliposomes include emulsions, suspensions, solutions, syrups, and elixirscontaining inert diluents commonly used in the art, such as purifiedwater. Besides the inert diluents, such compositions can also includeadjuvants, wetting agents, emulsifying and suspending agents, andsweetening, flavoring, and perfuming agents.

It is also possible for the antigenic preparations containing theSpirochaetales ROM proteins of the invention to include an adjuvant.Adjuvants are substances that can be used to nonspecifically augment aspecific immune response. Normally, the adjuvant and the antigen aremixed prior to presentation to the immune system, or presentedseparately, but into the same site of the animal being immunized.Adjuvants can be loosely divided into several groups based on theircomposition. These groups include oil adjuvants (for example, Freund'sComplete and Incomplete), mineral salts (for example, AlK(SO₄)₂,AlNa(SO₄)₂, AlNH₄ (SO₄), silica, alum, Al(OH)₃, Ca₃ (PO₄)₂, kaolin, andcarbon), polynucleotides (for example, poly IC and poly AU acids), andcertain natural substances (for example, wax D from Mycobacteriumtuberculosis, as well as substances found in Corynebacterium parvum,Bordetella pertussis, and members of the genus Brucella).

In another embodiment, a method of inducing an immune response topathogenic Spirochaetales, especially Treponema such as T. pallidumsubsp. pallidum; T. pailidum subsp. perfenne; T. pallidum subsp.endemicum; and T. ceratelum in animal is provided. Many differenttechniques exist for the timing of the immunizations when a multipleimmunization regimen is utilized. It is possible to use the antigenicpreparation of the invention more than once to increase the levels anddiversity of expression of the immune response of the immunized animal.Typically, if multiple immunizations are given, they will be spaced twoto four weeks apart. Subjects in which an immune response toSpirochaetaes is desirable include domestic animals and humans.

Generally, the dosage of ROM protein administered to an animal will varydepending on such factors as age, condition, sex and extent of disease,if any, and other variables which can be adjusted by one of ordinaryskill in the art.

The antigenic preparations of the invention can be administered aseither single or multiple dosages and can vary from about 10 ug to about1,000 ug of the Spirochaetales ROM antigenic protein per dose, morepreferably from about 50 ug to about 700 ug of ROM antigenic protein perdose, most preferably from about 50 ug to about 300 ug of ROM antigenicprotein per dose.

When used for immunotherapy, the monoclonal antibodies specific forSpirochaetales ROM proteins of the invention or fragments thereof may beunlabeled or labeled with a therapeutic agent. These markers can becoupled either directly or indirectly to the monoclonal antibodies ofthe invention. One example of indirect coupling is by use of a spacermoiety. These spacer moieties, in turn, can be either insoluble orsoluble (Diener, et al., Science, 231:148, 1986) and can be selected toenable drug release from the monoclonal antibody molecule at the targetsite. Examples of diagnostic markers that can be coupled to themonoclonal antibodies of the invention for immunotherapy of diseasestates associated with Spirochaetales such as T. pallidum are drugs,radioisotopes, lectins, and toxins. The labeled or unlabeled monoclonalantibodies of the invention can also be used in combination withtherapeutic agents such as those described above.

When the monoclonal antibody of the invention is used in combinationwith various therapeutic agents, such as those described herein, theadministration of the monoclonal antibody and the therapeutic agentusually occurs substantially contemporaneously. The term "substantiallycontemporaneously" means that the monoclonal antibody and therapeuticagent are administered reasonably close together with respect to time.Usually, it is preferred to administer the therapeutic agent before themonoclonal antibody. For example, the therapeutic agent can beadministered 1 to 6 days before the monoclonal antibody. Theadministration of the therapeutic agent can be daily, or at any otherinterval, depending upon such factors, for example, as the nature of thedisorder, the condition of the patient and half-life of the agent.

The dosage ranges for the administration of monoclonal antibodies of theinvention are those large enough to produce the desired effect in whichthe onset symptoms of the Spirochaetales disease are ameliorated. Thedosage should not be so large as to cause adverse side effects, such asunwanted cross-reactions, anaphylactic reactions, and the like.Generally, the dosage will vary with the age, condition, sex and extentof the disease in the subject and can be determined by one of skill inthe art. The dosage can be adjusted by the individual physician in theevent of any complication. Dosage can vary from about 0.1 mg/kg to about2000 mg/kg, preferably about 0.1 mg/kg to about 500 mg/kg, in one ormore dose administrations daily, for one or several days. Generally,when the monoclonal antibodies of the invention are administeredconjugated with therapeutic agents, lower dosages, comparable to thoseused for in vivo diagnostic imaging, can be used.

The monoclonal antibodies of the invention can be administeredparenterally by injection or by gradual perfusion over time. Themonoclonal antibodies of the invention can be administeredintravenously, intraperitoneally, intramuscularly, subcutaneously,intracavity, or transdermally, alone or in combination with effectorcells.

Preparations for parenteral administration include sterile aqueous ornon-aqueous solutions, suspensions, and emulsions. Examples ofnon-aqueous solvents are propylene glycol, polyethylene glycol,vegetable oils such as olive oil, and injectable organic esters such asethyl oleate. Aqueous carriers include water, alcoholicaqueoussolutions, emulsions or suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose, dextrose and sodium chloride, lactated Ringer's intravenousvehicles include fluid and nutrient replenishers, electrolytereplenishers (such as those based on Ringer's dextrose), and the like.Preservatives and other additives may also be present such as, forexample, antimicrobials anti-oxidants, chelating agents and inert gasesand the like.

In a further embodiment, the invention provides a method of detecting apathogenic Spirochaetaes-associated disorder in a subject comprisingcontacting a ROM protein of the Spirochaetales with an antibody specifictherefor. The antibodies are detectably labeled, for example, with adiagnostic radioisotope, a fluorescent compound, a bioluminescentcompound, a chemiluminescent compound, a metal chelator or an enzyme.Those of ordinary skill in the art will know of other suitable labelsfor binding to the antibody, or will be able to ascertain such, usingroutine experimentation.

For purposes of the invention, an antibody or nucleic acid probespecific for a Spirochaetales ROM protein may be used to detect thepresence of ROM protein or fragment thereof in biological fluids ortissues. Any specimen containing a detectable amount of ROM proteinantigen or polynucleotide can be used. A preferred specimen of thisinvention is blood, urine, cerebrospinal fluid, or tissue of skin(epidermis, dermis, and subcutaneous), spleen, liver, heart, brain, andbone origin.

Another technique that may also result in greater sensitivity consistsof coupling antibodies to low molecular weight haptens. These haptenscan then be specifically detected by means of a second reaction. Forexample, it is common to use such haptens as biotin, which reacts withavidin, or dinitrophenyl, pyridoxal, and fluorescein, which can reactwith specific antihapten antibodies.

Alternatively, the ROM proteins of this invention, or antibody-bindingfragments thereof, can be used to detect antibodies to SpirochaetalesROM proteins in a specimen. The ROM protein of the invention isparticularly suited for use in immunoassays in which it can be utilizedin liquid phase or bound to a solid phase carrier. In addition, ROMproteins used in these assays can be detectably labeled in various ways.

Examples of immunoassays that can utilize the antibodies or ROM proteinsof the invention are competitive and noncompetitive immunoassays ineither a direct or indirect format. Examples of such immunoassays arethe radioimmunoassay (RIA), the sandwich (immunometric assay) and theWestern blot assay. Detection of antibodies which bind to the ROMproteins of the invention can be done utilizing immunoassays that run ineither the forward, reverse, or simultaneous modes, includingimmunohistochemical assays on physiological samples. The concentrationof ROM protein used will vary depending on the type of immunoassay andnature of the detectable label used. However, regardless of the type ofimmunoassay used, the concentration of ROM protein utilized can bereadily determined by one of ordinary skill in the art using routineexperimentation.

The Spirochaetales ROM protein or antibody-binding fragments thereof ofthe invention can be bound to many different carriers and used to detectthe presence of antibody specifically reactive with the protein.Examples of well-known carriers include glass, polystyrene, polyvinylchloride, polypropylene, polyethylene, polycarbonate, dextran, nylon,amyloses, natural and modified celluloses, polyacrylamides, agaroses,and magnetite. The nature of the carrier can be either soluble orinsoluble for purposes of the invention. Those skilled in the art willknow of other suitable carriers for binding the ROM proteins of theinvention or will be able to ascertain such, using routineexperimentation.

There are many different labels and methods of labeling known to thoseof ordinary skill in the art. Examples of the types of labels which canbe used in the present invention include enzymes, radioisotopes,colloidal metals, fluorescent compounds, chemiluminescent compounds, andbioluminescent compounds.

For purposes of the invention, the antibody which binds to ROM proteinof the invention may be present in various biological fluids andtissues. Any sample containing a detectable amount of antibodies to ROMprotein can be used. Normally, a sample is a liquid such as urine,saliva, cerebrospinal fluid, blood, serum and the like, or a solid orsemi-solid such as tissue, feces and the like.

The monoclonal antibodies of the invention, directed towardSpirochaetales ROM proteins, are also useful for the in vivo detectionof antigen. The detectably labeled monoclonal antibody is given in adose that is diagnostically effective. The term "diagnosticallyeffective" means that the amount of detectably labeled monoclonalantibody is administered in sufficient quantity to enable detection ofSpirochaetales protein antigen for which the monoclonal antibodies arespecific.

The concentration of detectably labeled monoclonal antibody administeredshould be sufficient such that the binding to those cells, body fluid,or tissue having ROM protein is detectable compared to the background.Further, it is desirable that the detectably labeled monoclonal antibodybe rapidly cleared from the circulatory system in order to give the besttarget-to-background signal ratio.

As a rule, the dosage of detectably labeled monoclonal antibody for invivo diagnosis will vary depending on such factors as age, sex, andextent of disease of the subject. The dosage of monoclonal antibody canvary from about 0.001 mg/m² to about 500 mg/m²,preferably 0.1 mg/m² toabout 200 mg/m², most preferably about 0.1 mg/m² to about 10 mg/m². Suchdosages may vary, for example, depending on whether multiple injectionsare given, and other factors known to those of skill in the art.

For in vivo diagnostic imaging, the type of detection instrumentavailable is a major factor in selecting a given radioisotope. Theradioisotope chosen must have a type of decay which is detectable for agiven type of instrument. Still another important factor in selecting aradioisotope for in vivo diagnosis is that the half-life of theradioisotope be long enough so that it is still detectable at the timeof maximum uptake by the target, but short enough so that deleteriousradiation with respect to the host is minimized. Ideally, a radioisotopeused for in vivo imaging will lack a particle emission, but produce alarge number of photons in the 140-250 key range, which may be readilydetected by conventional gamma cameras.

For in vivo diagnosis, radioisotopes may be bound to immunoglobulineither directly or indirectly by using an intermediate functional group.Intermediate functional groups which often are used to bind radioactivemetallic ions to immunoglobulins are the bifunctional chelating agentssuch as diethylenetria minepentacetic acid (DTPA) andethylenediaminetetraacetic acid (EDTA) and similar molecules. Typicalexamples of metallic ions which can be bound to the monoclonalantibodies of the invention are ¹¹¹ In, ⁶⁷ Ga, ⁶⁸ GA, ⁷² As, ⁸⁹ Zr, ²⁰¹TI, and ^(99m) Tc.

The monoclonal antibodies of the invention can also be labeled with aparamagnetic isotope for purposes of in vivo diagnosis, as in magneticresonance imaging (MRI) or electron spin resonance (ESR). In general,any conventional method for visualizing diagnostic imaging can beutilized. Usually gamma and positron emitting radioisotopes are used forcamera imaging and paramagnetic isotopes for MRI. Elements which areparticularly useful in such techniques include ¹⁵⁷ GD, ⁵⁵ Mn, ¹⁶² Dy, ⁵²Cr, and ⁵⁶ Fe.

The monoclonal antibodies of the invention can be used to monitor thecourse of amelioration of Spirochaetales associated disorder. Thus, bymeasuring the increase or decrease of antibodies to ROM protein antigenpresent in various body fluids or tissues, it would be possible todetermine whether a particular therapeutic regiment aimed atameliorating the disorder is effective.

The materials for use in the method of the invention are ideally suitedfor the preparation of a kit. Such a kit may comprise a carrier meansbeing compartmentalized to receive in close confinement one or morecontainer means such as vials, tubes, and the like, each of thecontainer means comprising one of the separate elements to be used inthe method. For example, one of the container means may comprise aSpirochaetales ROM protein binding reagent, such as an antibody. Asecond container may further comprise ROM proteins or fragments. Theconstituents may be present in liquid or lyophilized form, as desired.

Monoclonal antibodies are made from antigen containing fragments of theprotein by methods well known in the art (Kohler, et al., supra, 1975).The term "antibody" as used in this invention is meant to include intactmolecules as well as fragments thereof, such as Fab and F(ab')₂, whichare capable of binding the epitopic determinant as well as geneticallyengineered antibody molecules such as single chain, chimeric, CDRgrafted antibodies, and variants thereof known to those skilled in theart.

The antibodies of the invention can be used in immunoaffinitychromatography for the isolation of protein fragments and amino acidsequences in ROM proteins containing antigenic activity of the presentinvention. One way to utilize immunoaffinit chromatography can beutilized is by the binding of the antibodies of the invention toCNBr-Sepharose-4B or Tresyl activated Sepharose (Pharmacia). These solidphase-bound antibodies can then be used to specifically bind sequencescontaining the antigenic activity of ROM proteins from mixtures of otherproteins to enable isolation and purification thereof. Bound sequencescan be eluted from the affinity chromatographic material usingtechniques known to those of ordinary skill in the art such as, forexample, chaotropic agents, low pH, or urea.

The invention provides polynucleotides encoding the isolated ROMproteins, preferably those of the genus Treponema, most preferably theROM proteins of T. pallidum shown in Table 1 above. Thesepolynucleotides include DNA, cDNA and RNA sequences which encode ROMproteins or antigenic fragments thereof. It is understood that allpolynucleotides encoding all or a portion of ROM proteins are alsoincluded herein, so long as they encode a polypeptide with antigenicactivity. Such polynucleotides include both naturally occurring andintentionally manipulated polynucleotides. For example, a ROM proteinmay be subjected to site-directed mutagenesis. The polynucleotides ofthe invention include sequences that are degenerate as a result of thegenetic code. There are only 20 natural amino acids, most of which arespecified by more than one codon. Therefore, as long as the amino acidsequence of the ROM protein is unchanged, or although changed retainsthe antigenic activity of the corresponding ROM protein, all degeneratenucleotide sequences are included in the invention.

As used herein the term "antigenic activity" shall mean the protein orpolypeptide binds with suitable affinity under physiologic conditions toan antibody known in the art to be associated with the disease statecaused by the pathogen from which the ROM protein or polypeptide isderived. Alternatively, "antigenic activity" means that the protein orpolypeptide binds with such affinity to an antibody specific to aSpirochaetaceae ROM protein isolated by the method of the presentinvention. DNA sequences of the invention can be isolated by severaltechniques known in the art. These include, but are not limited to: 1)hybridization of probes to genomic or cDNA libraries to detect sharednucleotide sequences, and 2) antibody screening of expression librariesto detect shared structural features.

Screening procedures which rely on nucleic acid hybridization make itpossible to isolate any gene sequence from any organism, provided theappropriate probe is available. For example, oligonucleotide probes,which correspond to a part of the sequence encoding the protein inquestion, can be synthesized chemically. This requires that short,oligopeptide stretches of amino acid sequence must be known, preferablyof at least 17 nucleotides in length. The DNA sequence encoding theprotein can be deduced from the genetic code, however, the degeneracy ofthe code must be taken into account. It is possible to perform a mixedaddition reaction when the sequence is degenerate. This includes aheterogenous mixture of denatured double-stranded DNA. For suchscreening, hybridization is preferably performed on eithersingle-stranded DNA or denatured double-stranded DNA. This is especiallyuseful in the detection of cDNA clones derived from sources where anextremely low amount of mRNA sequences relating to the polypeptide ofinterest are present. In other words, by using stringent hybridizationconditions directed to avoid non-specific binding, it is possible, forexample, to allow the autoradiographic visualization of a specific cDNAclone by hybridization of the target DNA to the single probe in themixture which is its complement (Wallace, et al., Nucleic Acid Research,9:879, 1981).

A cDNA expression library, such as λgtll, can be screened indirectly forROM polypeptides having at least one antigenic epitope, using antibodiesspecific for a ROM protein isolated from live pathogen according to themethod of this invention or antibodies from the blood of individualsinfected with the pathogen of interest previously identified as specificto the pathogen of interest. Such antibodies can be either monoclonal orpolyclonal and used to detect an expression product indicatve of thepresence of a ROM cDNA.

A ROM protein cDNA library can also be screened by injecting differentcDNAs into cocytes. After expression of the cDNA gene products occurs,the presence of the specific cDNA gene product can be identified byantibody screening with antibody specifically immunoreactive with ROMpolypeptides, for example. Alternatively, functional assays for ROMproteins of toxicogenic activity could be performed to identify ROMproteins producing oocytes.

Specific DNA sequences encoding Spirochaetales ROM proteins can also beobtained by: (1) isolation of double-stranded DNA sequences from genomicDNA; (2) chemical manufacture of a DNA sequence to provide the necessarycodons for the polypeptide of interest; and (3) in vitro synthesis of adouble-stranded DNA sequence by reverse transcription of MRNA isolatedfrom a eukarotic donor cell, resulting in a cDNA, or complimentary DNA.

Synthesis of DNA sequences is frequently the method chosen when theentire sequence of amino acid residues of the desired polypeptideproduct is known. When the entire sequence of amino acid residues of thedesired polypeptide is not known, the direct synthesis of DNA sequencesis not possible, and the method of choice is the formation of cDNAsequences. Among the standard procedures for isolating cDNA sequences ofinterest is the formation of plasmid or bacteriophage based cDNAlibraries in which MRNA is reverse transcribed from donor cells with ahigh level of genetic expression. When used in combination withpolymerase chain reaction (PCR) technology, less common MRNA species(cDNA) can be cloned as well. When significant portions of the aminoacid sequence of a polypeptide are known, labeled single ordouble-stranded DNA or RNA probes which represent a sequence present inthe target cDNA, may be used in DNA/DNA hybridization procedures whichare performed on cloned copies of the cDNA, which have been denaturedinto a single-stranded form (Jay, et al., Nucleic Acid Research,11:2325, 1983).

Since the novel DNA sequences of the invention encode a unique sequenceof ROM protein, it is now a routine matter to prepare, subclone, andexpress smaller polypeptide fragments of DNA from this or correspondingDNA sequences. Alternatively, by utilizing a DNA fragment, it ispossible, in conjunction with known techniques, to determine the DNAsequences encoding an entire ROM antigenic protein. Such techniques aredescribed in U.S. Pat. Nos. 4,394,443 and 4,446,235, which areincorporated herein by reference.

The polypeptide resulting from expression of a DNA sequence of theinvention can be further characterized as being free from associationwith other eukarotic polypeptides or other contaminants that mightotherwise be associated with the ROM protein in its natural cellularenvironment. Isolation and purification of microbially expressedpolypeptides provided by the invention may be by conventional meansincluding, preparative chromatographic separations and immunologicalseparations involving monoclonal and/or polyclonal antibody preparation.

For purposes of the present invention, ROM polypeptides that arehomologous to those of the invention can be identified by structural aswell as functional similarity. Structural similarity can be determined,for example, by assessing polynucleotide strand hybridization or byscreening with antibody, especially a monoclonal antibody, whichrecognizes a unique epitope present on a ROM protein disclosed in thisinvention. When hybridization is used as criteria to establishstructural similarity, those polynuclectide sequences that hybridizeunder stringent conditions to the polynucleotides of the invention areconsidered to be essentially the same as the polynucleotide sequences ofthe invention.

A wide variety of ways are available for introducing a polynucleotideexpressing a Spirochaetales ROM protein into the microorganism hostunder conditions which allow for stable maintenance and expression ofthe gene. DNA constructs are available which include the transcriptionaland translational regulatory signals for expression of the ROMpolynucleotide; the ROM gene under their regulatory control, and a DNAsequence homologous with a sequence in the host organism, wherebyintegration will occur; and/or a replication system which is functionalin the host, whereby integration or stable maintenance will occur.

The transcriptional initiation signals will include a promoter and atranscriptional initiation start site. In some instances, it may bedesirable to provide for regulative expression of the ROMpolynucleotide. This can be achieved with operators or a region bindingto an activator or enhancers that are capable of induction upon a changein the physical or chemical environment of the host. For example, atemperature sensitive regulatory region may be employed where theorganisms may be grown up in the laboratory without expression of theROM protein, but upon change in the growth conditions or environment,expression would begin. Other techniques may employ a specific nutrientmedium in the laboratory, which inhibits the expression of the ROMprotein, where the nutrient medium in the later environment would allowfor expression of the ROM protein. For translational initiation, aribosomal binding site and an initiation codon will be present.

Various manipulations may be employed for enhancing the expression ofthe mRNA, particularly by using an active promoter, as well as byemploying sequences, which enhance the stability of the mRNA. Theinitiation and translational termination region will involve stopcodon(s), a terminator region, and optionally, a polyadenylation signal.

In the direction of transcription, namely in the 5' to 3' direction ofthe coding or sense sequence, the construct will involve thetranscriptional regulatory region, if any, and the promoter, where theregulatory region may be either 5' or 3' of the promoter, the ribosomalbinding site, the initiation codon, the structural gene having an openreading frame in phase with the initiation codon, the stop codon(s), thepolyadenylation signal sequence, if any, and the terminator region. Thissequence as a double strand may be used by itself for transformation ofa microorganism host, but will usually be included with a DNA sequenceinvolving a marker, where the second DNA sequence may be joined to theexpression construct during introduction of the DNA into the host.

A marker structural gene may be present that provides for selection ofthose hosts that have been modified or transformed. The marker willnormally provide for selective advantage, for example, providing forbiocide resistance, for example, resistance to antibiotics or heavymetals; complementation, so as to provide prototropy to an auxotrophichost, or the like.

Where no functional replication system is present, the construct willalso include a sequence of at least 50 basepairs (bp), preferably atleast about 100 bp, and usually not more than about 1000 bp of asequence homologous with a sequence in the host. In this way, theprobability of legitimate recombination is enhanced, so that the genewill be integrated into the host and stably maintained by the host.Desirably, the ROM protein gene will be in close proximity to the geneproviding for complementation as well as the gene providing for thecompetitive advantage. Therefore, in the event that a ROM protein geneis lost, the resulting organism will be likely to also lose thecomplementing gene and/or the gene providing for the competitiveadvantage, so that it will be unable to compete in the environment withthe gene retaining the intact construct.

A large number of transcriptional regulatory regions are available froma wide variety of microorganism hosts, such as bacteria, bacteriophage,cyano-bacteria, algae, fungi, and the like. Various transcriptionalregulatory regions include the regions associated with the trp gene, lacgene, gal gene, the lambda left and right promoters, the Tac promoter,the naturally-occurring promoters associated with the ROM protein gene,where functional in the host. See, for example, U.S. Pat. Nos.4,332,898, 4,352,832 and 4,356,270. The termination region may be thetermination region normally associated with the transcriptionalinitiation region or a different transcriptional initiation region, solong as the two regions are compatible and functional in the host.

Where stable episomal maintenance or integration is desired, a plasmidwill be employed that has a replication system that is functional in thehost. The replication system may be derived from the chromosome, anepisomal element normally present in the host or a different host, or areplication system from a virus that is stable in the host. A largenumber of plasmids are available, such as pBR322, pACYC184, RSFI010,pR01614, and the like (see, for example Olson, et al., J. Bacteriol.150:6069, 1982, and Bagdasarian, et al., Gene, 16:237, 1981, and U.S.Pat. Nos. 4,356,270, 4,362,817, and 4,371,625.)

The ROM polynucleotide can be introduced between the transcriptional andtranslational initiation region and the transcriptional andtranslational termination region, so as to be under the regulatorycontrol of the initiation region. This construct will be included in aplasmid, which will include at least one replication system, but mayinclude more than one, where one replication system is employed forcloning during the development of the plasmid and the second replicationsystem is necessary for functioning in the ultimate host. In addition,one or more markers may be present, as described above. Whereintegration is desired, the plasmid will desirably include a sequencehomologous with the host genome.

The transformants can be isolated in accordance with conventionaltechniques usually employing selection of the desired organism asagainst unmodified organisms or transferring organisms, when present.The transformants then can be screened for pesticidal activity.

As hosts, of particular interest will be the prokaryotes and the lowereukaryotes, such as fungi. Illustrative prokaryotes, both Gram-negativeand -positive, include Enterobacteriaceae, such as Escherichia, Ervinia,Shigella, Salmonella, and Proteus; Bacillaceae, Rhizobiceae, such asRhizobium; Spirillaceae, such as photobacterium, Zymomonas, Serratia,Aeromonas, Vibrio, Desulfovibrio, Spirfillum; Lactobacillaceae;Pseudomonadaceae, such as Pseudomonas and Acetobacter; Azotobacteraceaeand Nitrobacteraceae. Among eukaryotes are fungi, such as Phycomycetesand Ascomycetes, which includes yeast, such as Saccharomyces andSchizosaccharomyces; and Basidiomycetes yeast, such as Rhodotorula,Aureobasidium, Sporobolomyces, and the like.

Host organisms of particular interest include yeast, such as Rhodotorulasp., Aureobasidium sp., Saccharomyces sp., and Sporobolomyces sp.;phylloplane organisms such as Pseudomonas sp., Erwinia sp. andFlavobacterium sp.; or such other organisms as Escherichia,Lactobacillus sp., Bacillus sp., and the like. Specific organismsinclude Pseudomonas aeruginosa, Pseudomonas fluorescens, Saccharomycescerevisiae, Bacillus thuringiensis, Escherichia coli, Bacillus subtilis,and the like.

In general, expression vectors containing promotor sequences whichfacilitate the efficient transcription of the inserted genetic sequenceare used in connection with the host. As described above, biologicallyfunctional viral or plasmid DNA vectors capable of expression andreplication in a host are known in the art. Such vectors are used toincorporate ROM protein encoding DNA sequences of the invention.Expression vectors typically contain an origin of replication, apromoter, and a terminator, as well as specific genes that are capableof providing phenotypic selection of the transformed cells.

Transformation of the host cell with the recombinant DNA may be carriedout by conventional techniques well known to those skilled in the art.Where the host is prokaryotic, such as E. coli, competent cells whichare capable of DNA uptake can be prepared from cells harvested afterexponential growth and subsequently treated by the CaCl₂ method usingprocedures well known in the art. Alternatively, MgCL₂ or RbCl could beused.

Where the host used is a eukaryote, various methods of DNA transfer canbe used. These include transfection of DNA by calciumphosphate-precipitates, conventional mechanical procedures such asmicroinjection or electroporation, insertion of a plasmid encased inliposomes, or the use of viral vectors.

Eukaryotic host cells may also include yeast. For example, DNA can beexpressed in yeast by inserting the DNA into appropriate expressionvectors and introducing the product into the host cells. Various shuttlevectors for the expression of foreign genes in yeast have been reported(Heinemann, J. et al., Nature, 340:205, 1989; Rose, et al., Gene,60:237, 1987).

Isolation and purification of microbially expressed protein, orfragments thereof provided by the invention, may be carried out byconventional means including preparative chromatography andimmunological separations involving monoclonal or polyclonal antibodies.Antibodies provided in the present invention are immunoreactive with theSpirochaetales ROM proteins of the invention. Antibody which consistsessentially of pooled monoclonal antibodies with different epitopicspecificities, as well as distinct monoclonal antibody preparations areprovided. Monoclonal antibodies are made from antigen containingfragments of the ROM protein by methods well known in the art (Kohler,et al., supra, 1975; Current Protocols in Molecular Biology, Ausubel, etal., ed., 1989).

Minor modifications of the ROM protein primary amino acid sequence mayresult in polypeptides that have substantially equivalent antigenicactivity compared to the ROM proteins and polypeptides described herein.Such modifications may be deliberate, as by site-directed mutagenesis,or may be spontaneous. All proteins produced by these modifications areincluded herein as long as the antigenic activity for antibodiesspecific to ROM proteins is present.

The composition of the amino acids of the ROM proteins of this inventioncan be determined by methods well known in the art, for instance, thePhenylthiohydantoine (PTH) method of Edman, et al. (Europ. J. Biochem.,1:30, 1967). Briefly, in this method the purified protein is dried undervacuum and redissolved in a small volume of acetonitrile 95% plus TFA(0.08%). The concentrated sample is then introduced into a gaseous phasesequencer connected to a phenylthiohydantoine (PTH) analyzer. From theamino acid sequence so obtained, a DNA sequence encoding the protein canbe deduced using routine methods well known in the art.

Alternatively, to discover the nueleotide sequence of DNA materialobtained using the methods of this invention, double stranded dideoxysequencing can be performed, for example on a DuPont Genesis 2000, usingthe DuPont Genesis 2000 sequencing kit according to the manufacturer'sinstructions. Post gel processing can be done with the Base Caller 5.0program (DuPont, Boston, Mass.). Alternatively, a DNA sequence of theclone can be obtained using a Sequenase® II kit (United StatesBiochemical, Cleveland, Ohio) on the automated DNA sequencer Genesis2000 (Dupont, Wilmington, Del.) according to the manufacturer'sinstructions. The DNA encoding the gene may also be chemicallysynthesized (Merrifield, J. Am. Chem. Soc., 85 pp. 2149 (1963)), orgenerated by PCR.

The following examples illustrate the manner in which the invention canbe practiced. It is understood, however, that the examples are for thepurpose of illustration and the invention is not to be regarded aslimited to any of the specific materials or conditions therein.

EXAMPLE 1

Source of Treponemes

T. pallidum, subsp. pallidum, Nichols strain, was maintained bytesticular passage in New Zealand White rabbits as described previously(Miller, et al., Br. J. Vener, Dis., 39:195, 1963). Animals used toprepare T. pallidum outer membrane and antigen for sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) were injectedintramuscularly with 10 mg of cortisone acetate (Merck Sharp & Dohme,Rahway, N.J.) per kg of body weight from days 3 through 12 afterinfection.

T. vincentii was grown in spirolate broth (Gibco) supplemented with 10%heat-inactivated rabbit serum. Approximately 300 ml of culturecontaining 2×10⁸ organisms/ml was centrifuged at 10,000×g for 15 min.The resulting treponemal pellet was resuspended in 140 ml of phosphatebuffered saline (PBS), pH 7.2, and used for outer membrane isolations orrecentrifuged as described for use as antigen in SDS-PAGE.

Purification of T. pailidum

A total of 300 ml of PBS, pH 7.2, In 50 ml volumes was used to extracttreponemes from 20 infected rabbit testicles. The treponemal suspension,containing approximately 6×10¹⁰ organisms was subjected to two low speedcentrifugations at 4000×g in order to remove gross tissue debris.Treponemes were then pelleted by centrifugation at 20K×g for 15 minfollowed by resuspension in 40 ml of PBS containing 0.5% Bovine serumalbumin (BSA; Intergen Co., Purchase, N.Y.) and 7% FICOLL™ densitygradient separation medium (Pharmacia, Piscataway, N.J.). Tenmilliliters (10 ml) of suspension was layered onto 25 ml of adiscontinuous Ficoll/PBS gradient with increasing buoyant densities of1.045, 1.055, 1.065, and 1.075, and 1.085 g/ml. After centrifugation at7K×g for 15 min, several bands were observed in the gradient. Previousstudies using darkfield and electron microscopy of the four interdensityzones have shown "clean" single treponemes within the two upper zones(1.065-1.055 and 1.055-1.045) and some clumped and single treponemesplus host cell debris within the two lower zones (1.085-1.075 and1.075-1065). Only treponemes recovered from the uppermost zone gradientby needle aspiration, followed by a 4-fold dilution in PBS, were usedfor subsequent experiments. The resulting suspension was usedimmediately for extraction of the outer membrane.

EXAMPLE 2

Isolation of T. pallidum and T. vincentii Outer Membrane

To 140 ml of treponemal suspension obtained in Example 1 containingapproximately 5×10¹⁰ treponemes was added 200 ul of R18 octyl-decylRhodamine chloride (Molecular Probes, Inc., Eugene, Oreg.). Thesuspension was incubated at room temperature for 10 min and thencentrifuged at 8K×g for 20 min. For removal of the outer membrane, thetreponemal pellet was resuspended into 60 ml of ice cold 0.05M sodiumcitrate buffer, pH 3.2, and incubated on a rocker with occasionalvortexing for 2 hrs at room temperature to release the outer membranefrom the inner membrane. The suspension was then centrifuged three timesat 8K×g for 15 min in order to remove treponemal protoplasmic cylinders.The supernatant containing released outer membrane was then neutralizedusing 1M Tris-HCl, pH 9.0, and centrifuged at 150K×g for 16 hrs at 15°C. The resulting membrane pellet was resuspended into 2 ml of PBS,layered onto 36 ml of a continuous 5-40% sucrose/PBS gradient for T.pallidum or 10-40% gradient for T. vincentii, and centrifuged at 100 K×gfor 16 hrs at 15° C. Following centrifugation, the outer membrane band,identified visually by Rhodamine labeling, was needle aspirated, diluted7-fold with PBS, and recentrifuged at 150K g for 5 hr. The finalpurified membrane pellet was resuspended in 100 ul of PBS containing 1mM EDTA, 1 mM PMSF, and stored at 4° C. As shown in FIG. 1B, the citratebuffer treated organisms showed release of outer membrane.

EXAMPLE 3

Electron Microscopy (EM) and Freeze-Fracture EM

For electron microscopy, a PARLODION® grid film cover (Mallinckrodt,Inc., St. Louis, Mo.) and carbon-coated 300-mesh copper grids (TedPella, Inc., Redding, Calif.) were floated for 5 min on 40 ul specimendrops. After 3 washes in PBS and 2 washes in double-distilled water, thegrids were negatively stained with 1% uranyl acetate and examined in anelectron microscope (JEOL 100 CX) at 80 kV accelerating voltage.Freeze-fracture EM of outer membrane vesicles was performed as follows.Fifty microliters (50 ul) of membrane suspension was pelleted bycentrifugation at 200K×g for 3 hrs and resuspended in 1 ul of 20%glycerol in double-distilled water. A 0.5 ul sample was placed on astandard Balzars specimen holder (Balzars Co., Redding, Calif.) andfrozen by immersion in liquid propane (-1900° C.) using aguillotine-type device. Frozen samples were transferred under liquidnitrogen to the specimen stage of a Salzars 400K freeze-fractureapparatus precooled to -150° C. Frozen samples were fractured at -120°C.by using a knife cooled at the temperature of liquid nitrogen. Thefracture surface was immediately replicated with platinum-carbon at45°C. and carbon at 90° C. The replicas were floated in 3-4% sodiumhypochlorite to bleach the organic material and washed three times indouble-distilled water. The replicas were then placed on Formvar-coatedfreeze-fracture grids (Ted Pella, Inc.) and observed by electronmicroscopy as described above. The electron micrograph shown in FIG. 2Dshows few intramembranous protein particles.

EXAMPLE 4

Isolation of ROMs from Outer Membrane Using One and Two DimensionalSDS-PAGE

SDS-polyacrylamide slab gels were run by using the discontinuous buffersystem of Laemmli (Laemmli, Nature, London, U.K., 227:680-685, 1970).Samples containing 5×10⁸ whole organisms or 1 to 5×10⁹ treponemalequivalents of membrane material were boiled for 10 min in final samplebuffer containing 4% SDS, 10% 2-mercaptoethanol, and 0.01% bromphenolblue in 62.5 mM Tris buffer, pH 6.8 (FSB); for some samples, urea at afinal concentration of 8M (FSB-U) was included. In some experiments,samples were solubilized in FSB containing proteinase K (Sigma ChemicalCo., St. Louis, Mo.) at a concentration of 100 ug/ml and incubated for 1hr at 37° C. before boiling. Two-dimensional gel electrophoresis wasperformed as described by O'Farrell (J. Biol. Chem., 250:4007-4021,1975) with minor modifications. Outer membrane material containing from5×10⁹ to 3×10¹⁰ treponemal equivalents was first solubilized for 1 hr atroom temperature in lysis buffer containing 9M urea, 2% Nonidet P-40(NP40) (Sigma Chemical Co., St. Louis, Mo.) and 2% carrier ampholytes atpH 9.5. Isoelectric focusing was carried out for 18 hrs at a constantvoltage of 600 v in 0.2 cm×12 cm tube gels containing 2% pH 5-7 and 0.8%pH 3-10 Ampholines (BioRad, Richmond Calif.), 2% NP40, and 9M urea. Thesecond dimension consisted of standard SDS-PAGE as described above.After electrophoresis, gels were stained with Coomassie brilliant blueor transferred to polyvinylidene defluoride (PVDF) membranes (Millipore,Bedford, Mass.) as previously described (Towbin, et al., Porc. Natl.Acad. Sci. USA, 76:4350-4354, 1979). Following transfer, PVDF membraneswere stained with 1% Amido Black or Aurogold Forte (Amersham, UK). Forimmunoblotting, PVDF membranes were incubated for 1 hr with serumdiluted 1:1000 in PBS containing 5% nonfat dry milk (Carnation Co., LosAngeles, Calif.) and 0.1% Tween-20 (Sigma Chemical Co., St. Louis, Mo.)(MT-PBS). Antibody-antigen binding was detected using the enhancedchemiluminescence (ECL) system of Amersham (Amersham, UK). Blots wereincubated for 1 hr in anti-rabbit 1 g or anti-mouse 1 g conjugated tohorseradish peroxidase diluted 1:2500 in MT-PBS. Blots were next washedin PBS containing 0.1% Tween-20, incubated for 1 min in the ECLdeveloping reagents (Amersham, UK), and then autoradiographed with KodakX-AR5 film. The Coomassie stained gel is shown in FIG. 1A, and the PVDFimmunoblot is shown in FIG. 2A.

EXAMPLE 5

Detection of T. pallidum Penicillin Binding Proteins

Penicillin binding proteins (PBPs) of T. pallidum were identified using¹²⁵ Iodine-labeled penicillin-V as follows. Sodium(trimethylstannyl)phenoxyacetamidopenicillin (Lilly Laboratories, EliLilly and Company, Indianapolis, Ind.), was labeled with Na¹²⁵ Iodineusing chloramine-T as previously described (Preston, et al., Antmicrob.Agents Chemother., 34:718-721, 1990). Equal volumes of ¹²⁵I-penicillin-V were combined with 1×10⁸ Ficoll purified T. pallidum,1×10⁸ T. pallidum protoplasmic cylinders, and 5×10⁹ treponemalequivalents of outer membrane. Suspensions were incubated at roomtemperature for 30 minutes prior to centrifugation at 10×g for 15minutes for whole organisms and protoplasmic cylinders, and at 100K×gfor 1 hr for outer membrane material. Pellets were resuspended in FSBand electrophoresed by the SDS-PAGE, using conditions described above.Following electrophoresis, the gel was vacuum dried and thenautoradiographed with Kodak X-AR5 film at room temperature for 24 hrs.The results are shown in FIG. 4.

EXAMPLE 6

Preparation of Antisera from Syphilitic Rabbits

Serum from syphilitic rabbits immune to challenge (immune rabbit serum;IRS) was acquired 6 months post-infection intratesticularly with 4×10 T.pallidum Antiserum against the T. pallidum recombinant 4D protein wasprepared as described previously (Radolf, et al., supra., 1986).Monoclonal antibodies against the T. pallidum 47-kDa lipoprotein (MAbIIE3) and against the 42-kDa TmpA lipoprotein were kindly provided byDr. Michael V. Norgard, Universit of Texas (Chamberlain, et al., supra.,1989) and Drs. Jan vanEmben and Leo Schouls, University of Bilthoven,Netherlands (Schouls, et al., Microb. Pathog., 7:175-188, 1989),respectively. Anti-rabbit serum proteins were purchased from SigmaChemical Co., St. Louis, Mo.

EXAMPLE 7

Preparation of Control Antisera

Antiserum against T. vincentii was generated in rabbits as follows.Approximately 1×10⁹ PBS washed T. vincentii organisms were disrupted bysonication, combined with Freund's complete adjuvant, and injected bothintramuscularly (1M) and subcutaneously (SC). After 3 weeks, animalswere boosted 1M and SC using a similarly prepared suspension in Freund'sincomplete adjuvant. Animals were bled one week following the boostimmunization.

EXAMPLE 8

Isolation of the T. pallidum and T. vincentii outer Membrane

The present outer membrane isolation procedure comprises the use ofseveral novel steps including (1) a Ficoll gradient to purify T.pallidum, octyl-decyl rhodamine to label membranes, (2) use of alipid-soluble dye marker, preferably a fluorescent dye marker thatintercalates into the outer membrane and (3) a low ionic strength andlow pH buffer for the selective removal of the outer membrane.

Ficoll purification of T. pallidum resulted in significant removal ofhost contaminating proteins as determined by SDS-PAGE as shown in FIG.1A, and immunoblotting using anti-rabbit whole serum, as shown in FIG.1B. Ficoll purified T. pallidum and PBS washed T. vincentii were treatedwith 0.05M Citrate buffer which resulted in the release of membrane asmonitored by fluorescent microscopy of rhodamine labeled material (datanot shown) and by electron microscopy as shown in FIG. 2B. After 45mins, the majority of treponemes had significantly narrower diametersconsistent with the removal of their outer membranes. The absence ofendoflagellar filaments, which are dissociated to flagellin at low pH(Blanco, et al., supra., 1988), may have also contributed to the releaseof outer membrane material. Comparison by SDS-PAGE of the protoplasmiccylinders from citrate treated treponemes with those of whole treponemesshowed a similar profile and intensity of stained proteins (data notshown) indicating that treponemes were not disrupted by this procedure.Sucrose gradient purification of membrane material yielded a singlerhodamine labeled band at the 7% sucrose gradient for T. pallidum and atthe 35% sucrose gradient for T. vincentii as determined by refractiveindex analysis (data not shown). The membrane nature of this materialwas demonstrated by electron microscopy, which showed membrane vesiclesthat ranged in diameter from approximately 300 to 700 nm as shown inFIG. 2C.

EXAMPLE 9

Freeze-Fracture Electron Microscopy of Membrane Vesicles

Purified membrane vesicles were analyzed by freeze-fracture electronmicroscopy in order to determine intramembranous particle composition asshown in FIG. 2D. Membrane vesicles from both T. pallidum and T.vincentii contained extremely few protein particles. Of 200 T. pallidumvesicles observed, only 8 were found to have fracture faces containingparticles; the number of particles in these fracture faces ranged from 1to 3. By comparison, of 50 T. vincentii vesicles observed, 22 hadfracture faces containing at least 1 particle. Total particleenumeration showed that the membrane particle density of T. pallidum wasapproximately six times less than that of T. vincentii. In contrast, thefraction faces of T. pailidum and T. vincentii protoplasmic cylinderinner membranes and of host tissue membranous material acquired fromnoninfected rabbits contained a relatively high density of particles(data not shown).

Composition of T. vincentii Outer Membrane Vesicles

The detection of the T. vincentii LPS stepladder by immunoblot analysisof proteinase K (PK) treated membrane, protoplasmic cylinder, and wholeorganism fractions was used to assess the efficiency of outer membranerecovery. As shown in FIG. 3, the number and intensity of LPS bandsdetected from 1×10⁹ equivalents of outer membrane material was similarto that of 2×10⁸ equivalents of whole organisms. By comparison, 2×10⁸equivalents of protoplasmic cylinders showed a marked decrease in thenumber and intensity of its LPS stepladder bands. These results indicatethat approximately 20% of the T. vincentii outer membrane was recovered.

Immunoblots of the T. vincentii outer membrane untreated with PK probedwith antisera generated against whole organisms as described in Example6 above and Coomassie stained SDS-PAGE (data not shown) also detectedtwo antigenic proteins with molecular masses of approximately 65- and55-kDa.

Composition of T. pallidum Outer Membrane Vesicles

Detection of inner membrane associated penicillin binding proteins(PBPs) was used to assess the purity of isolated outer membrane(Cunningham, et al., supra., 1987; Radolf, et al., supra, 1989). 1×10⁸whole T. pallidum organism (Tp) and protoplasmic cylinders and 5×10⁹equivalents of outer membrane (OM) were incubated with ¹²⁵ I-labeledpenicillin V prior to SDS-PAGE and autoradiography. As shown in FIG. 4,major PBPXs of 94-, 80-, 58-, 43-, and 38-kDa were detected in the wholeorganism and protoplasmic cylinder preparations but not in thetreponemal equivalents of outer membrane material, indicating theabsence of inner membrane contamination.

In order to determine the extent of periplasmic protein contamination,5×10⁹ treponemal equivalents of outer membrane material and 1×10⁸ wholeorganisms were probed on immunoblots with specific antiserum against the19-kDa proplasmic cylinder associated protein 4D (Radolf, et al., supra,1989), specific antiserum against the endoflagella (Champion, et al.,Infect. Immun., 58:3158-3161, 1990), and a monoclonal antibody againstthe 47-kDa major lipoprotein (Chamberlain, et al., supra, 1989). Theresults shown in FIG. 5 detect no 47-kDa lipoprotein or 4D protein.Further, only trace amounts of endoflagella were detected, correspondingto approximately 0.2% endoflagellar contamination based upon a 10-folddecrease in the relative intensities of endoflagellar bands detected ascompared to those of 1×10⁸ whole organisms. These findings indicate thatthe outer membrane preparation was essentially free from contaminationby three constituents present in the at periplasm of T. pallidum.

Consistent with the known paucity of outer membrane protein in T.pallidum (Radolf, et al., Proc. Natl. Acad. Sci. USA, 86:2051-2055,1989; Walker, et al., supra, 1989) and the above freeze-fracture EMfindings, Coomassie stained SDS-PAGE of approximately 5×10⁹ treponemalequivalents of membrane material failed to detect any major proteinbands (data not shown). The initial identification of membraneassociated protein was determined antigenically using immune rabbitantisera (IRS) and enhanced chemiluminescence (ECL). The 5×10⁹equivalents of T. pallidum outer membrane material were prepared insample buffer, with and without 8M urea, before being probed with IRS.As shown in FIG. 6, three prominently reacting bands at 17-, 32-, and45-kD were detected in the absence of 8M urea. Solubilization ofmembrane material in the presence of 8M urea resulted in the loss of the32-kDa band, but not the 17 and 45-kDa proteins, suggesting only twomajor antigenic species. This finding was confirmed by two dimensional(2D) immunoblot analysis as shown in FIG. 7. The 17-kDa protein had a plof greater than 7 and showed additional oligomeric forms at 32- and45-kDa, while the 45-kDa protein showed a single spot at a pI ofapproximately 5.5. The 45-kDa protein was subsequently identified as theTmpA lipoprotein (Hansen, et al., supra, 1985) using specific monoclonalantibodies (data not shown). Longer exposed autoradiograms of these 2Dimmunoblots also identified spots corresponding to the pI's of theendoflagellar proteins (data not shown).

In addition to the 17-kda, TmpA, and endoflagellar proteins, goldstained 2D immunoblots of SDS-PAGE gels (shown in FIG. 8) containing3×10¹⁰ treponemal equivalents of outer membrane which were subjected toisoelectric focusing (IEF) pH 5 to 7, showed five additional proteins,including two separate spots with different pI's at 31-kDa and singlespots at 28-, 65-, and 68-kDa. While the 68-kDa protein was shown byimmunoblot analysis to be rabbit albumin, all of the other proteinsreacted specifically with low dilutions of IRS, indicating their originin T. pallidum (data not shown).

EXAMPLE 10

Cloning of the Tromp1 gene

To isolate the Tromp1 gene, two different degenerate mixedoligonucleotides, designated 31-A and 31-C, were made to the amino acidsequence of a tryptic digest amino acid sequence analysis peptide(AHDMQE) and (EEAEFD), respectively, generated from the 31-kda nativeprotein (pI 6.7) obtained from the outer membrane of Treponema pallidum.The primers were used in a PCR reaction with the 7 to 9 kb fragment ofgenomic T. pallidum DNA prepared by digestion with EcoRI. A T. pallidumgenomic library was made by partially digesting the DNA with EcoRI,AluI, RsaI, and HaeIII. Following digestion, the DNA was purified andEcoRI-adapted. The restriction fragments were subsequently cloned intothe λZAP II phage cloning system (Stratagene, San Diego, Calif.) andprobed with the PCR product generated using the above described 31-A and31-C mixed oligonucleotides. From this library, 4 clones, designated 2A,2B, 3, and 6, were identified with the probe. Following plaquepurification, PCR was performed on each phage clone to determine theactual insert size of DNA. The insert size for clones 2A and 3 were bothapproximately 1600 bp. Clone 2B had an insert size of approximately 1300bp. The insert size for clone 6 was too large to determine by PCR, butwas estimated to be greater than 8 kbp.

Attempts were made to convert all 4 clones into the pBluescript SK(-)plasmid form (Stratagene, San Diego, Calif.) by in vivo excision.However, results of this attempt indicated that clones 2A, 3, and 6 wereexpressing a product toxic to the E. coli cells harboring the plasmids.The indication of toxicity was the very slow rate at which the cellswere growing. Upon continued cultivation on solid media, the cells beganto lose parts of the insert DNA, upon which subsequent growth becamenormal.

It was observed that clone 2A appeared to be slightly less toxic thanthe other two clones. Therefore, this clone was chosen for furtheranalysis. In order to obtain intact recombinant DNA, clone 2A was grownfor a very short time on LB agar plate solid media (Gibco BRL,Gaithersberg, Md.) and then cells were scraped off for plasmid DNApreparation. The DNA appeared to be intact based on the insert size ofapproximately 1600 bp when digested with EcoRI. In order to reduce thetoxicity of the protein to the host E. coli, the 1600 bp fragment wassubsequently restricted into three fragments of approximately 872, 700,and 80 bp by digestion with HindIII. All three fragments weresuccessfully subcloned back into pbluescript plasmid and were no longertoxic to E. coli.

EXAMPLE 11

DNA sequence of Tromp1

An open reading frame was identified in the 872 bp HindIII fragment 313bp downstream from the HindIII site. This fragment encoded 161 aminoacids. The remainder of the gene was shown to reside on both the 80 bpand 700 bp fragments. All together, the gene was found to consist of anopen reading frame 867 bp. The sequence of the 867 bp fragment (SEQUENCEI.D. NO. 1) was obtained using well known dideoxy sequencing techniquesof Sanger et al. (See Sambrook, et al., Molecular Cloning A LaboratoryManual, Second Edition, Cold Spring Harbor Laboratory Press, 1989). Thegene encodes a precursor protein TROMP1 of 288 amino acids (31,742 Da)having the deduced amino acid sequence of SEQUENCE I.D. NO. 2.

The first 32 residues from the N-terminus of TROMP1 has characteristicsof a hydrophobic signal peptide including a 13 residue N-regioncontaining four basic charged residues (Histidine, Lysine, Histidine,and Arginine), an H-region containing 11 consecutive hydrophobic aminoacids, and a C-region containing a putative concensus leader peptidase 1cleavage site of Threonine-Histidine-Alanine. The mature processedprotein consists of 256 amino acids with a calculated mass of 28,182 Da.As determined by inspection and Kyte-Doolittle hydropathy analysis,which identified areas of hydrophobicity and hydrophilicity, the aminoacid sequence analysis of the mature protein shows considerable andregular amphiphatic beta-pleated sheet secondary structure correspondingto outer membrane spanning regions. Moreover, the terminal beta-sheetmembrane spanning region shows features consistent with other well knowngram-negative bacterial outer membrane proteins, including a glycineresidue in the terminal 6th position and terminating in phenylalanine.

The foregoing description of the invention is exemplary for purposes ofillustration and explanation. It should be understood that variousmodifications can be made without departing from the spirit and scope ofthe invention. Accordingly, the following claims are intended to beinterpreted to embrace all such modifications.

SUMMARY OF SEQUENCES

SEQ ID NO:1 is the nucleotide sequence encoding a precursor TROMPprotein.

SEQ ID NO: 2 is the deduced amino acid sequence of TROMP1, a precursorTROMP protein encoded by SEQ ID NO:1.

    __________________________________________________________________________    SEQUENCE LISTING                                                              (1) GENERAL INFORMATION:                                                      (iii) NUMBER OF SEQUENCES: 2                                                  (2) INFORMATION FOR SEQ ID NO:1:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 957 base pairs                                                    (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: DNA (genomic)                                             (vii) IMMEDIATE SOURCE:                                                       (B) CLONE: TROMP1                                                             (ix) FEATURE:                                                                 (A) NAME/KEY: CDS                                                             (B) LOCATION: 1..954                                                          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                       ATGCATCAAAATTCACCCAAGCAGTGTCACTTGATACGTGAAAGAATA48                            MetHisGlnAsnSerProLysGlnCysHisLeuIleArgGluArgIle                              151015                                                                        TGTGCCTGCGTGCTCGCGCTTGGCATGCTGACCGGTTTTACGCACGCA96                            CysAlaCysValLeuAlaLeuGlyMetLeuThrGlyPheThrHisAla                              202530                                                                        TTCGGTAGCAAGGATGCCGCAGCGGACGGGAAACCCCTGGTTGTCACC144                           PheGlySerLysAspAlaAlaAlaAspGlyLysProLeuValValThr                              354045                                                                        ACCATTGGCATGATAGCGGATGCTGTCAAAAACATCGCTCAAGGTGAT192                           ThrIleGlyMetIleAlaAspAlaValLysAsnIleAlaGlnGlyAsp                              505560                                                                        GTGCATCTAAAGGGGTTGATGGGTCCTGGTGTTGACCCGCACCTGTAC240                           ValHisLeuLysGlyLeuMetGlyProGlyValAspProHisLeuTyr                              65707580                                                                      ACGGCTACTGCGGGGGATGTGGAATGGCTCGGGAATGCGGATCTCATC288                           ThrAlaThrAlaGlyAspValGluTrpLeuGlyAsnAlaAspLeuIle                              859095                                                                        CTGTACAACGGGTTGCACCTGGAAACCAAGATGGGCGAGGTGTTTTCC336                           LeuTyrAsnGlyLeuHisLeuGluThrLysMetGlyGluValPheSer                              100105110                                                                     AAACTGCGCGGGAGCCGCTTGGTAGTTGCAGTTTCTGAGACTATTCCG384                           LysLeuArgGlySerArgLeuValValAlaValSerGluThrIlePro                              115120125                                                                     GTGTCTCAGCGTCTTTCTCTTGAGGAAGCAGAGTTCGATCCGCATGTG432                           ValSerGlnArgLeuSerLeuGluGluAlaGluPheAspProHisVal                              130135140                                                                     TGGTTTGATGTAAAGCTGTGGTCTTATTCGGTGAAGGCAGTGTACGAA480                           TrpPheAspValLysLeuTrpSerTyrSerValLysAlaValTyrGlu                              145150155160                                                                  AGCTTGTGCAAGCTGTTGCCGGGAAAAACTCGCGAATTTACTCAACGT528                           SerLeuCysLysLeuLeuProGlyLysThrArgGluPheThrGlnArg                              165170175                                                                     TATCAGGCGTACCAGCAGCAGTTGGATAAGCTTGACGCGTACGTTCGG576                           TyrGlnAlaTyrGlnGlnGlnLeuAspLysLeuAspAlaTyrValArg                              180185190                                                                     CGCAAGGCGCAGTCGCTGCCTGCTGAAAGGCGTGTGTTGGTGACCGCT624                           ArgLysAlaGlnSerLeuProAlaGluArgArgValLeuValThrAla                              195200205                                                                     CATGATGCGTTCGGCTATTTTAGCCGTGCGTATGGTTTTGAGGTGAAG672                           HisAspAlaPheGlyTyrPheSerArgAlaTyrGlyPheGluValLys                              210215220                                                                     GGGTTGCAAGGGGTGAGCACCGCTTCGGAAGCCAGTGCGCATGATATG720                           GlyLeuGlnGlyValSerThrAlaSerGluAlaSerAlaHisAspMet                              225230235240                                                                  CAGGAACTGGCAGCGTTTATTGCGCAGCGTAAACTCCCTGCTATCTTT768                           GlnGluLeuAlaAlaPheIleAlaGlnArgLysLeuProAlaIlePhe                              245250255                                                                     ATTGAGAGTTCTATTCCGCACAAAAACGTTGAAGCGTTAAGGGATGCG816                           IleGluSerSerIleProHisLysAsnValGluAlaLeuArgAspAla                              260265270                                                                     GTGCAGGCAAGAGGGCACGTAGTGCAGATTGGAGGCGAGTTGTTTTCT864                           ValGlnAlaArgGlyHisValValGlnIleGlyGlyGluLeuPheSer                              275280285                                                                     GATGCGATGGGGGATGCGGGTACGAGCGAGGGTACCTACGTAGGGATG912                           AspAlaMetGlyAspAlaGlyThrSerGluGlyThrTyrValGlyMet                              290295300                                                                     GTAACACACAATATCGATACGATCGTTGCTGCGTTGGCTCGC954                                 ValThrHisAsnIleAspThrIleValAlaAlaLeuAlaArg                                    305310315                                                                     TAG957                                                                        (2) INFORMATION FOR SEQ ID NO:2:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 318 amino acids                                                   (B) TYPE: amino acid                                                          (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: protein                                                   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                       MetHisGlnAsnSerProLysGlnCysHisLeuIleArgGluArgIle                              151015                                                                        CysAlaCysValLeuAlaLeuGlyMetLeuThrGlyPheThrHisAla                              202530                                                                        PheGlySerLysAspAlaAlaAlaAspGlyLysProLeuValValThr                              354045                                                                        ThrIleGlyMetIleAlaAspAlaValLysAsnIleAlaGlnGlyAsp                              505560                                                                        ValHisLeuLysGlyLeuMetGlyProGlyValAspProHisLeuTyr                              65707580                                                                      ThrAlaThrAlaGlyAspValGluTrpLeuGlyAsnAlaAspLeuIle                              859095                                                                        LeuTyrAsnGlyLeuHisLeuGluThrLysMetGlyGluValPheSer                              100105110                                                                     LysLeuArgGlySerArgLeuValValAlaValSerGluThrIlePro                              115120125                                                                     ValSerGlnArgLeuSerLeuGluGluAlaGluPheAspProHisVal                              130135140                                                                     TrpPheAspValLysLeuTrpSerTyrSerValLysAlaValTyrGlu                              145150155160                                                                  SerLeuCysLysLeuLeuProGlyLysThrArgGluPheThrGlnArg                              165170175                                                                     TyrGlnAlaTyrGlnGlnGlnLeuAspLysLeuAspAlaTyrValArg                              180185190                                                                     ArgLysAlaGlnSerLeuProAlaGluArgArgValLeuValThrAla                              195200205                                                                     HisAspAlaPheGlyTyrPheSerArgAlaTyrGlyPheGluValLys                              210215220                                                                     GlyLeuGlnGlyValSerThrAlaSerGluAlaSerAlaHisAspMet                              225230235240                                                                  GlnGluLeuAlaAlaPheIleAlaGlnArgLysLeuProAlaIlePhe                              245250255                                                                     IleGluSerSerIleProHisLysAsnValGluAlaLeuArgAspAla                              260265270                                                                     ValGlnAlaArgGlyHisValValGlnIleGlyGlyGluLeuPheSer                              275280285                                                                     AspAlaMetGlyAspAlaGlyThrSerGluGlyThrTyrValGlyMet                              290295300                                                                     ValThrHisAsnIleAspThrIleValAlaAlaLeuAlaArg                                    305310315                                                                     __________________________________________________________________________

We claim:
 1. An isolated nucleic acid fragment that encodes the proteinof SEQ ID NO:2.
 2. The nucleic acid fragment of claim 1 having thesequence of SEQ ID. NO:1.
 3. The nucleic acid fragment of claim 2wherein T is U.
 4. A nucleic acid fragment that is the complement of SEQID:1, or a fragment thereof at least 17 bases in length that willselectively hybridize to DNA which encodes the protein of SEQ ID NO:2.5. A recombinant expression vector including the nucleic acid fragmentof claim
 1. 6. A recombinant expression vector including the nucleicacid fragment of claim 2 or
 4. 7. The vector of claim 6, wherein thevector is a plasmid.
 8. A host cell stably transformed with the vectorof claim
 7. 9. The host cell of claim 8, wherein the cell is eukaryotic.10. The host cell of claim 8, wherein the cell is prokaryotic.
 11. Amethod for preparing an isolated rare outer membrane protein of T.pallidum which comprises culturing the host cell of claim 8, 9 or 10,and recovering a rare outer membrane protein of T. pallidum.